2024-516148-24-00招募中3 期
A phase III, randomized, double-blinded study of the efficacy and safety of LEvetiracetam to prevent Seizures in Symptomatic Alzheimer's Disease in adults with Down syndrome (the LESS-AD trial).
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau5 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2025年5月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 5
- 主要终点
- Efficacy: Number (percentage) of subjects who do not develop a bilateral tonic-clonic epileptic seizure during the study (96 weeks). Therefore, a non-responder, or treatment failure, is defined as any subject who develops a bilateral tonic-clonic epileptic seizure during the study.
研究概览
简要总结
To evaluate the efficacy of levetiracetam as a preventive measure for bilateral tonic-clonic seizures at 96 weeks in adults with Alzheimer's disease associated with Down syndrome.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Diagnosed with Down Syndrome (DS), either with a karyotype or a compatible typical phenotype.
- •Symptomatic Alzheimer’s Disease (AD) dementia, based on change in functionality and neuropsychological tests’ results. Different cut-off points will be established to diagnose dementia depending on the level of intellectual disability of the individual, according to previous experience (Benejam et al; 2020): in adults with mild intellectual disability, a CAMCOG-DS score of 80 and an mCRT score of 29 will be chosen, whereas values of 56 and 28, respectively, will be used in subjects with moderate intellectual disability. Doubtful cases (e.g., with compromised functionality, but without alteration in the neuropsychological assessment) or those unable to complete the evaluation will be categorized by consensus among expert clinicians, using all available clinical information.
- •Willing and able caregiver who has daily contact with the study subject.
- •Subjects and caregivers must be able to comply with the prescribed regimen of study treatment throughout the course of the study and meet a minimum required time commitment of biannual in-person visits
- •Any concurrent treatment for AD approved by the European Medicines Agency (EMA) must be stable for at least 30 days prior to screening and at least 60 days prior to study day
- •Other medications (except for those listed under exclusion criteria) are allowed as long as the dose is stable for 30 days prior to screening
- •Age over 40 years at time of screening. This age cutoff has been selected because the beginning of cognitive decline attributable to AD in the study population is exceptional below this age
- •Subjects and/or their caregivers must be able to provide their consent before participating in any study-related procedures. A thorough description of the informed consent process can be found under section 12.
- •Participants’ Informed Consent Process.
排除标准
- •Cognitive changes attributable to causes other than AD (for example, but not limited to, uncorrected visual or hearing deficit, severe, untreated sleep apnea or uncontrolled thyroid disorders).
- •Significant risk of suicide, defined using the C-SSRS as the subject answering “yes” to suicidal ideation questions 4 or 5 or answering “yes” to suicidal behavior within the past 12 months
- •Deviations from normal values for hematologic parameters, liver function tests, and other biochemical measures, judged to be clinically significant by the investigator.
- •Pregnant and breastfeeding patients
- •Participation in another clinical trial within 3 months of screening.
- •Hypersensitivity to the active ingredient, other pyrrolidone derivatives, or any of the excipients
- •Previous history of adult-onset epileptic seizures (over 18 years old).
- •Treatment with any kind of antiepileptic drugs, benzodiazepines, narcotics.
- •Significant comorbidities or analytical abnormalities, such as:
- •Any unstable and/or clinically significant medical condition likely to hamper the evaluation of safety and/or efficacy of the study (eg, moderate and/or severe untreated obstructive sleep apnea, clinically significant reduction in serum B12 or folate levels, clinically significant abnormalities of thyroid function, stroke, or other cerebrovascular conditions), as per investigator’s judgement.
- •Severe renal dysfunction (creatinine clearance < 30 mL/min), which would affect serum levetiracetam levels, or any other medical condition which is determined by the investigators to potentially create an undue risk for an adverse effect
- •Concomitant or past history psychiatric or neurologic disorder other than those considered to be related to AD (eg, head injury with loss of consciousness, symptomatic stroke, Parkinson’s disease, severe carotid occlusive disease, transient ischemic attacks [TIAs]).
结局指标
主要结局
Efficacy: Number (percentage) of subjects who do not develop a bilateral tonic-clonic epileptic seizure during the study (96 weeks). Therefore, a non-responder, or treatment failure, is defined as any subject who develops a bilateral tonic-clonic epileptic seizure during the study.
Efficacy: Number (percentage) of subjects who do not develop a bilateral tonic-clonic epileptic seizure during the study (96 weeks). Therefore, a non-responder, or treatment failure, is defined as any subject who develops a bilateral tonic-clonic epileptic seizure during the study.
次要结局
- Time to first bilateral tonic-clonic epileptic seizure (days)
- All-cause mortality: - Number (percentage) of patients dying from any cause during the study. - Number (percentage) of patients dying due to AD complications during the study. - Time to death (days).
- AD-related biomarkers: - Cognition: The neuropsychological assessment will include the CAMCOG-DS, mCRT
- Plasma biomarkers: plasma concentrations of 217-pTau and NfL (pg/mL).
- Neuroimaging biomarkers (MRI): Volumetric measures extracted for 12 subcortical gray matter regions (six left and six right, including the amygdala, caudate nucleus accumbens, pallidum, putamen, and thalamus), the left and right hippocampi, and the left and right lateral ventricles. Cortical thickness measure extracted for 34 left-hemispheric gray matter regions, and 34 right hemispheric gray matter regions (Whelan et al, Brain 2018).
- Electroencephalography (EEG): Appearance of graphoelements with irritative characteristics: spike-wave, polyspike-wave, acute wave and spike or focal and generalized slowing of the activity, power spectrum analysis and synchronization by bands.
- - Safety: The primary endpoints are number, type, frequency, and intensity of AEs evaluated until the end of treatment and assessment of tolerability during the medical visit, physical and neurological examination, vital signs, brain MRI assessment, suicidality (as measured with the C-SSRS), routine hematology and biochemistry evaluation in blood.
研究者
Alejandra Espinosa
Scientific
Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
研究点 (5)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary GeneralizationPartial SeizuresEpilepsyNCT01392768Ache Laboratorios Farmaceuticos S.A.126
已完成
3 期
A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)Generalized Tonic-Clonic SeizuresEpilepsyNCT01228747UCB Japan Co. Ltd.361
已完成
4 期
Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure PreventionTraumatic Brain InjurySubarachnoid HemorrhageNCT00618436University of Cincinnati52
已完成
不适用
Levetiracetam for Treatment of Pain Associated With FibromyalgiaFibromyalgiaNCT00254657University of California, San Francisco66
招募中
3 期
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Generalized Myasthenia GravisNCT06456580Vor Biopharma180